Provided is a drug or a method that uses a p38 MAP kinase inhibitor (in particular AKP-001), such as a pyrimidinyl isoxazole derivative or a pyridyl isoxazole derivative, to treat or prevent a corneal endothelial condition, disorder or disease caused by transforming growth factor beta (TGF-ß) signalling in corneal endothelial cells. In a preferred embodiment, the corneal endothelial condition, disorder or disease caused by TGF-ß signalling is Fuchs corneal endothelial dystrophy.
